Feng, Yuanqing
Xie, Ning http://orcid.org/0000-0002-6559-2997
Inoue, Fumitaka http://orcid.org/0000-0003-0657-434X
Fan, Shaohua http://orcid.org/0000-0003-0610-9106
Saskin, Joshua http://orcid.org/0000-0001-5372-9696
Zhang, Chao
Zhang, Fang
Hansen, Matthew E. B. http://orcid.org/0000-0002-1183-4137
Nyambo, Thomas
Mpoloka, Sununguko Wata
Mokone, Gaonyadiwe George
Fokunang, Charles
Belay, Gurja
Njamnshi, Alfred K. http://orcid.org/0000-0003-0052-1511
Marks, Michael S. http://orcid.org/0000-0001-7435-7262
Oancea, Elena
Ahituv, Nadav http://orcid.org/0000-0002-7434-8144
Tishkoff, Sarah A. http://orcid.org/0000-0001-9164-1628
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (3UM1HG009408-02S1, 3UM1HG009408-02S1)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1R01GM113657-01)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (5R01AR076241-02, P30-AR069589-03, 5R01AR076241-02, 5R01AR076241-02)
Article History
Received: 15 September 2022
Accepted: 28 November 2023
First Online: 10 January 2024
Competing interests
: N.A. is an equity holder of Encoded Therapeutics, a gene regulation therapeutics company and is a cofounder and scientific advisor of Regel Therapeutics and Neomer Diagnostics. The remaining authors declare no competing financial interests.